Indications for using video-assisted thoracoscopic surgery to diagnose diaphragmatic injuries after penetrating chest trauma.

BACKGROUND: Video-assisted thoracoscopic surgery (VATS) has been shown to be an accurate method for identifying diaphragmatic injuries (DIs). The purpose of this investigation was to establish specific indications for the use of VATS after penetrating chest trauma. METHODS: A retrospective review of all patients undergoing VATS after penetrating chest trauma at a level 1 trauma center over an 8-year period was performed. Logistic regression was used in an attempt to identify independent predictors of DI. RESULTS: One hundred seventy-one patients underwent VATS assessment of a hemidiaphragm, and 60 patients (35%) were found to have a DI. Five independent risk factors for DI were identified from analyzing the patient records: abnormal chest radiograph, associated intraabdominal injuries, high-velocity mechanism of injury, entrance wound inferior to the nipple line or scapula, and right-sided entrance wound. CONCLUSIONS: In the largest published series of patients undergoing VATS to exclude a DI, this review identifies five independent predictors of DI after penetrating chest trauma. A diagnostic algorithm incorporating these five factors was designed with the goal of reducing the number of unrecognized DIs after penetrating chest trauma by using VATS for patients at greatest risk for such injuries.

Port site metastasis after laparoscopic staging of esophageal carcinoma.

The case history of a patient who underwent laparoscopic staging of an esophageal carcinoma is presented. After neoadjuvant chemoradiation therapy a port site metastasis was found at esophagectomy. Possible etiologies, implications for the continued use of minimally invasive staging for esophageal carcinoma, and prevention of port site metastasis are discussed.

Thoracoscopic localization of nonpalpable rib tumors for excisional biopsy.

Nonpalpable tumors of the rib can be difficult to localize accurately at the time of excisional biopsy. Furthermore, the ability of current imaging techniques to assess pleural or pulmonary involvement is not reliable. An intraoperative localization method using single port thoracoscopy is discussed which allows optimal placement of a biopsy incision and provides an accurate assessment of any tumor invasion into the adjacent pleura or lung.

Descending necrotizing mediastinitis: An analysis of the effects of serial surgical debridement on patient mortality.

OBJECTIVES: Descending necrotizing mediastinitis is a polymicrobial infection originating in the oropharynx with previously reported mortality rates of 25% to 40%. This investigation reviews the effects of serial surgical drainage and debridement on the survival of patients with descending necrotizing mediastinitis. METHODS: A retrospective review of patients from 1980 through 1998 with a diagnosis of descending necrotizing mediastinitis was performed. Their records were abstracted for personal demographics, hospital course, morbidity, and mortality. Also abstracted were all reports of patients with descending necrotizing mediastinitis published in English between 1970 and 1999. RESULTS: We treated 10 patients in whom descending necrotizing mediastinitis was identified. The mean age of the patients was 38 years. They underwent a mean of 6 +/- 4 computed tomographic imaging studies, 4 +/- 1 transcervical drainage procedures, and 2 +/- 1 transthoracic drainage procedures. Three patients required abdominal exploration and 4 underwent tracheostomy. No deaths occurred. In contrast, 96 patients with descending necrotizing mediastinitis were identified from the literature with a mean age of 38 years. They underwent a mean of 2 +/- 1 computed tomographic imaging studies, 2 +/- 1 transcervical drainage procedures, and 0.7 + 0.3 transthoracic drainage procedures. Sixteen (17%) patients required abdominal exploration and 34 (35%) underwent tracheostomy. Twenty-eight (29%) patients from the literature cohort died during their treatment. CONCLUSION: Descending necrotizing mediastinitis remains a life-threatening infection. On the basis of experience accrued in treating these patients, an algorithm incorporating computed tomographic imaging for diagnosis and surveillance and serial transcervical and transthoracic operative drainage is outlined in the hope of reducing the excessive mortality of descending necrotizing mediastinitis.

Meconium has no lecithin or sphingomyelin but affects the lecithin/sphingomyelin ratio.

OBJECTIVE: Although a few studies have evaluated the effect of meconium on the lecithin/sphingomyelin ratio for testing of fetal lung maturity, to date these studies have assessed only the lecithin-sphingomyelin ratio of amniotic fluid contaminated with meconium. The purpose of this study was (1) to determine whether meconium by itself has a lecithin/sphingomyelin ratio and, if so, (2) to determine whether the lecithin/sphingomyelin ratio is constant. STUDY DESIGN: A lecithin/sphingomyelin ratio was obtained by standard thin-layer chromatography on the first meconium stool of 20 neonates between 31 weeks and term. A quantitative assay was then performed on a sample from each gestational age (7 samples ranging from 31 weeks to term) to confirm the presence of lecithin and sphingomyelin. RESULTS: The 20 samples had atypical thin-layer chromatographic migratory patterns in the zones for lecithin and sphingomyelin. The presumed lecithin/sphingomyelin ratios ranged from 1.1 to 3.6, with no correlation with gestational age. However, the quantitative assay did not detect the presence of lecithin or sphingomyelin in any of the analyzed samples. CONCLUSIONS: Meconium does not appear to contain lecithin or sphingomyelin but has an unidentified moiety whose migratory pattern, as shown by qualitative standard thin-layer chromatography, is similar to that of lecithin with sphingomyelin. Therefore the presence of meconium in amniotic fluid may falsely raise or lower the lecithin/sphingomyelin ratio and confuse fetal lung maturity interpretations.

Antepartum cervical ripening: applying prostaglandin E2 gel in conjunction with scheduled nonstress tests in postdate pregnancies.

OBJECTIVE: Our purpose was to evaluate whether inserting prostaglandin E2 gel at the time of scheduled nonstress tests in patients with postdate pregnancies can decrease rates of intervention. STUDY DESIGN: A multicenter pilot study enrolled women with postdate pregnancies with Bishop score < or = 6 who were undergoing antepartum fetal heart rate testing. Patients were randomized in a double-blind fashion to receive either a prostaglandin E2 intracervical gel (Prepidil) or a placebo gel after each of their scheduled nonstress tests. RESULTS: There were no significant differences in the number of antepartum tests, labor inductions, or cesarean sections, the maximum oxytocin dosage, or the interval from admission to delivery in the prostaglandin E2 gel and placebo gel groups (n = 90). In the subset of patients with a Bishop score between 3 and 6 (63 patients), there were fewer inductions in the prostaglandin E2 group (30% vs 55%, P < .05). CONCLUSION: Application of prostaglandin E2 gel at the time of scheduled antepartum testing in patients with postdate pregnancies with unfavorable cervices decreased the induction rate only among patients with intermediate Bishop scores.

Intralobar bronchopulmonary sequestration presenting as hemoptysis: evidence for an acquired cause.

A 26-year-old pregnant female was treated for an intralobar sequestration presenting as exsanguinating hemoptysis. The case brings forth strong evidence supporting an acquired rather than a congenital cause of some intralobar sequestrations. We discuss the anatomy, epidemiology, and pathogenesis of bronchopulmonary sequestrations.

The treatment of low cardiac output syndrome following cardiopulmonary bypass using delayed sternal closure.

The purpose of this study, was to ascertain whether delayed sternal closure (DSC) could eliminate the need for an intra-aortic balloon pump (IABP) or ventricular assist device (VAD) in patients with low cardiac output syndrome (LCOS) following coronary artery bypass grafting surgery (CABG). To investigate this, the records of 3014 patients undergoing CABG were retrospectively reviewed. Sixty (2.0%) patients had a relative or absolute contraindication to IABP or VAD use and required DSC for LCOS. DSC resolved 45 (75%) of these patients' LCOS, requiring an average of 1.6 +/- 0.7 days and producing a mean change in cardiac index of +1.0 +/- 0.3 L/min/m2. Fifteen (25%) of these patients did not resolve their LCOS after DSC and required either an IABP (11) or a VAD (4). Significant postoperative morbidity occurred in 22 (36.7%) patients but were not related to DSC. Only one (1.7%) sternal wound infection occurred from a total of 147 patient-days of DSC. Operative mortality was 47 per cent (28) but was not unexpected based on the number of urgent/emergent (48; 80%) and reoperative (40; 67%) procedures but does not appear to be related to the technique of DSC. DSC appears to be a simple and safe method for treating LCOS following CABG. It is effective in resolving the majority of patients' LCOS without the addition of any significant morbidity. DSC also spares these patients the added morbidity, mortality, and cost associated with circulatory assist devices.

The surgical complications of Ehlers-Danlos syndrome.

Between January 1975 and July 1995, 44 gastrointestinal and 45 vascular complications of Ehlers-Danlos syndrome type IV (EDS-IV) were reported in the literature. This included 41 colon perforations, 2 paraesophageal hernias, 22 spontaneous hemorrhages, 17 aneurysms, and 5 arterial dissections. Twenty-seven colonic perforations were treated with resection and diversion, 11 with total abdominal colectomy (TAC), and 3 with primary colon repair. Reperforation occurred in 15 resection/diversion patients versus none treated with TAC (P < 0.05). Seven patients (23.3%) died from their gastrointestinal complications. Eleven vascular complications were treated with nonoperative management, eight with vessel ligation, 20 with arterial reconstruction, and two with therapeutic angiography. Eighteen patients underwent angiography, with three (22%) major complications and one death (5.6%). Twelve (30%) patients died from vascular complications of EDS-IV, seven of whom had been treated with arterial reconstruction (P < 0.05). This review supports treating colon perforations in EDS-IV patients with TAC and end ileostomy to avoid a reperforation or an anastamotic leak. EDS-IV patients with vascular complications should be treated with nonoperative therapy and noninvasive imaging techniques when possible. Operative intervention, when required, should focus on simple vessel ligation rather than reconstruction.

Low levels of interrater reliability in a standard measure of outcome in eating disorders (the modified Morgan-Russell Assessment Schedule).

OBJECTIVE: The interrater reliability of the modified version of the widely used Morgan-Russell Assessment Schedule was assessed. METHOD: Sixty-six female patients presenting for treatment for the first time in a general hospital and a community health center were assessed by a treating clinician and a researcher during sequential interviews. Two extra items were added to the Schedule to allow for the assessment of bulimic behaviors. Ratings were analyzed using the Cohen's weighted kappa. RESULTS: Poor to very poor levels of agreement were found between rater pairs assessing the 66 separate patients. DISCUSSION: The necessity for a specific, standardized format in using the Morgan-Russell Schedule is discussed. In its current, unstandardized format the Schedule may not be suitable for comparing outcome in eating disorders across different centers.

Cost reduction by combined carotid endarterectomy and coronary artery bypass grafting.

A significant cost reduction is likely if patients who require coronary artery bypass grafting with significant carotid stenosis have simultaneous carotid endarterectomy and bypass grafting, provided risk is not increased. To investigate this issue, we retrospectively identified cases from February 1977 to May 1994 with first-time isolated carotid endarterectomy, coronary bypass, or combined procedures. In the isolated carotid endarterectomy population, median age was 69 years and 58% (85/146) were male, as compared with 68 years and 68% (68/100) male in the combined group; median age of the coronary bypass cohort was 65 years and 76% (381/500) male. A significantly higher percentage of patients in the coronary bypass versus combined group were in New York Heart Association functional class IV. In the combined group there was a significantly higher incidence of older age, diabetes, hypertension, hyperlipidemia, renal failure, and congestive heart failure. There was no difference among the three groups with respect to hospital mortality (0%, 3.4%, and 4.0%, respectively) and permanent stroke (0.7%, 1.2%, and 0%, respectively). Hospital costs were $4,896, $10,959 and $11,089, respectively, with a savings of $4,766 (30%), and Medicare hospital reimbursement was $8,575, $23,071, and $23,071, respectively, with a savings of $10,077 (25.3%). Thus, in appropriate patients, a combined procedure is cost effective, eliminating a second surgical procedure and the cost of the postoperative stay (3.7 +/- 2.4 days) associated with isolated carotid endarterectomy. Risk of permanent stroke or death is not increased.

Evaluation of the nonreactive positive contraction stress test prior to 32 weeks: the role of the biophysical profile.

A nonreactive positive contraction stress test in a pregnancy near term is an indication for delivery. Such nonreassuring antepartum testing combined with severe prematurity presents a management dilemma. Ideally, prolongation of selected pregnancies would allow time for corticosteroid therapy and fetal maturation. Prior to 32 weeks' gestation, we utilized the biophysical profile to select patients for continued intrauterine management as an alternative to immediate delivery. Continued surveillance was undertaken if the fetus had a reassuring biophysical profile score; immediate delivery by cesarean section was undertaken if the biophysical profile score was nonreassuring. This approach allowed a mean gain of 13 days in utero for the continued surveillance group. There was no evidence of further fetal compromise in this group based on umbilical cord pH or 5-minute Apgar scores. These data suggest that the biophysical profile can be safely used to prolong selected preterm pregnancies with nonreactive positive contraction stress tests without adversely affecting the initial neonatal metabolic status.

Antepartum surveillance for a history of stillbirth: when to begin?

OBJECTIVE: A history of stillbirth is universally accepted as an indication for antepartum fetal heart rate testing. Our goal was to examine when fetal testing should begin in an otherwise healthy patient with a history of stillbirth. STUDY DESIGN: This is a nonconcurrent cohort study of patients who were seen for antepartum surveillance from January 1979 to December 1991 with a history of stillbirth as the only indication for testing. Subsequent pregnancies were evaluated for adverse outcomes and abnormal antepartum test results. RESULTS: There was one case of recurrent stillbirth among the 300 study patients. Nineteen patients (6.4%) had one or more positive antepartum surveillance tests (positive contraction stress test or biophysical profile < or = 4). Three patients (1%) had positive tests before 32 weeks, all of whom were subsequently delivered without incident at term. Three patients were delivered for positive tests at < 36 weeks, one by cesarean section for fetal distress. We could not detect a relationship between the gestational age of the previous stillborn and the incidence of abnormal tests or fetal distress in subsequent pregnancies. CONCLUSION: Antepartum surveillance should begin at > or = 32 weeks in the healthy pregnant woman with a history of stillbirth.

The value of a negative antepartum test: contraction stress test and modified biophysical profile.

OBJECTIVE: To examine the outcome of pregnancies in high-risk patients whose last antepartum fetal assessment was a negative contraction stress test (CST) or a negative modified biophysical profile. METHODS: Twenty-nine hundred ninety-four women who received modified biophysical profiles were compared with 2450 who had CSTs during the preceding 3 years. Pregnancy outcomes were evaluated in patients whose last test was negative. RESULTS: Seventeen hundred fifty-three patients had negative modified biophysical profiles as the last test before delivery, and 1337 had negative CSTs as the last test before delivery. Adverse perinatal outcomes included perinatal death or death before nursery discharge, cesarean delivery for fetal distress within the first 2 hours of labor, 5-minute Apgar score less than 7, neonatal seizures, or grade III or grade IV central nervous system hemorrhage. Adverse outcomes occurred in 90 patients (5.1%) whose last test before delivery was a negative modified biophysical profile and in 93 patients (7.0%) whose last test was a negative CST (P = .04, odds ratio 1.38, 95% confidence interval 1.01-1.88). Overall, there were 11 perinatal deaths, nine of which resulted from lethal congenital abnormalities. CONCLUSIONS: In this population, the frequency of adverse perinatal outcome following a negative modified biophysical profile was no greater than that following a negative CST. Further, the incidence of potentially preventable perinatal death following a negative modified biophysical profile or CST was less than one per 1000 tested high-risk pregnancies.

Perinatal outcome with the modified biophysical profile.

OBJECTIVE: Our purpose was to evaluate perinatal outcomes in high-risk pregnancies monitored with a modified biophysical profile. STUDY DESIGN: All non-insulin-dependent patients referred for antepartum fetal surveillance received a modified biophysical profile biweekly. A modified biophysical profile is a combination of a nonstress test and an amniotic fluid index. Patients with a singleton gestation and intact membranes were entered into a protocol of randomized backup testing for an abnormal modified biophysical profile. Those patients having a nonreactive fetal heart rate, significant variable decelerations, late decelerations, or an amniotic fluid index < or = 5.0 cm received either a contraction stress test or a biophysical profile immediately. Once randomized, a patient received the same backup test, when indicated, with subsequent testing. RESULTS: A total of 2774 patients had 17,429 tests with an uncorrected perinatal mortality rate of 2.9 per 1000. The overall incidence of an adverse perinatal outcome (i.e., perinatal death or nursery death before infant hospital discharge, cesarean delivery for fetal distress within the first 2 hours of labor, 5-minute Apgar score < 7, neonatal seizures or grade III or IV central nervous system hemorrhage) was 7.0%. When compared with patients having persistently normal modified biophysical profile, patients requiring a backup test had a significantly greater incidence of adverse perinatal outcome (9.3% vs 4.9%, p < 0.001, odds ratio 2.0, 95% confidence interval 1.5 to 2.7) and small-for-gestational-age infants (5.2% vs 2.4%, p < 0.001, odds ratio 2.2, 95% confidence interval 1.5 to 3.5). No differences in outcomes between patients randomized to a contraction stress test versus a biophysical profile could be identified either overall or in limiting the analysis to outcome after a negative last test. However, patients having contraction stress test as a backup test had a significantly higher rate of intervention for an abnormal test result than did those having a biophysical profile backup test (23.7% vs 16.6%, p < 0.002, odds ratio 1.6, 95% confidence interval 1.2 to 2.1). CONCLUSION: The modified biophysical profile is an excellent means of fetal surveillance and identifies a group of patients at increased risk for adverse perinatal outcome and small-for-gestational-age infants. There does not appear to be a significant benefit with the contraction stress test compared with the biophysical profile as a backup test. Further, the contraction stress test is associated with a higher rate of intervention for an abnormal test than is the biophysical profile.

Use of Amniostat-FLM in detecting the presence of phosphatidylglycerol in vaginal pool samples in preterm premature rupture of membranes.

OBJECTIVE: The presence of phosphatidylglycerol in amniotic fluid from the vaginal pool has been established as a reliable marker of pulmonary maturity in pregnancies complicated by preterm premature rupture of membranes because its presence is not affected by contaminants. This study was undertaken to determine the distribution of positive phosphatidylglycerol relative to gestational age from vaginal pool amniotic fluid samples and to assess the efficacy and accuracy of the Amniostat-FLM (Hana Biologics; Irvine Scientific after Sept. 14, 1989), an antibody agglutination method for rapidly detecting phosphatidylglycerol. STUDY DESIGN: All singleton nondiabetic pregnancies between 26 and 36 weeks with premature rupture of membranes from whom a vaginal pool sample was obtained were studied. The percent positive by gestational age was analyzed. The neonates that were delivered with a positive phosphatidylglycerol were evaluated for the presence of hyaline membrane disease and other immediate sequelae of prematurity. RESULTS: Of the 201 vaginal pool amniotic fluid samples assayed for phosphatidylglycerol with the Amniostat-FLM procedure, 18% (36/201) were positive for phosphatidylglycerol and none of the delivered infants developed hyaline membrane disease. CONCLUSION: The Amniostat-FLM seems to be accurate in predicting pulmonary maturity from vaginal pool samples.

Antepartum fetal surveillance in patients with diabetes: when to start?

OBJECTIVE: Although antepartum fetal well-being testing is an accepted practice in the management of diabetic patients, there are few data suggesting when to start. Our goal was to examine when testing should be started in the pregnant diabetic woman. STUDY DESIGN: Antepartum test results and patient histories were prospectively collected on all diabetic pregnancies from January 1981 through December 1991. The data were retrospectively analyzed for when fetal compromise became evident. Fetal compromise was defined as stillbirth, first positive contraction stress test, or intervention because of an abnormal antepartum fetal test result. RESULTS: Six hundred fourteen patients were enrolled in the study. There were three stillbirths, 45 (7.4%) patients had at least one positive contraction stress test, and 71 (11.6%) patients were delivered because of an abnormal fetal test result. Those with early compromise (< or = 34 weeks' gestation) could not be identified solely by diabetic class. The majority of patients (73%) requiring early intervention because of an abnormal test were class R or F diabetic patients with a growth-retarded fetus or were patients who had a concomitant diagnosis of hypertension. CONCLUSIONS: Class R or F diabetic patients or diabetic patients with a growth-retarded fetus or a concomitant diagnosis of hypertension may require testing to be started as early as 26 weeks' gestation. Otherwise, testing may be safely delayed until 32 weeks' gestation.

How frequently should the amniotic fluid index be repeated?

OBJECTIVE: Our objective was to determine the most appropriate interval for assessing amniotic fluid volume with amniotic fluid index. STUDY DESIGN: In a retrospective analysis amniotic fluid indexes performed every 3 to 4 days in antepartum testing patients were compared with their follow-up values. Of 10,742 amniotic fluid indexes there were 7393 with follow-up values within 4 days. The results were stratified by current amniotic fluid index, gestational age, and concurrent nonstress test results. The groups were compared with chi 2 analysis. RESULTS: Patients with normal amniotic fluid index (> or = 8 cm) had a 0.54% chance of oligohydramnios developing in the next 4 days. Those patients with low normal amniotic fluid indexes (5 to 8 cm) had a 5% chance of oligohydramnios developing within the next 4 days, and patients with low amniotic fluid indexes (< or = 5 cm) had a 59% chance of persistent oligohydramnios 4 days after the index examination. Subdividing by gestational age demonstrated that patients > or = 41 weeks' gestation had a 2.6% chance of oligohydramnios developing within 4 days if current amniotic fluid index was between 8 and 15 cm. Results of concurrent fetal heart rate findings did not appear to change the risk for development of oligohydramnios. CONCLUSION: In patients < 41 weeks' gestation with normal amniotic fluid indexes, a repeat amniotic fluid index is not necessary for 7 days.

A randomized, placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24 to 28 weeks' gestation.

Previous randomized controlled studies of corticosteroids for the reduction of respiratory distress syndrome have failed to demonstrate benefit in very early premature gestational age groups. A randomized, double-blind, placebo-controlled clinical trial of betamethasone given to mothers with intact membranes and threatened premature delivery between 24 and 28 weeks of pregnancy was conducted. Thirty-six patients were randomized to receive betamethasone, two doses of 12 mg, 24 hours apart, and 41 received placebo. No difference was found in the overall incidence of respiratory distress syndrome between the two groups (betamethasone vs placebo 0.55 vs 0.66) or in the incidence of respiratory distress syndrome in babies delivered between 1 and 7 days after the first dose of drug (betamethasone vs placebo 0.78 vs 0.88). Nor were there any differences observed in any measure of severity of respiratory distress syndrome between the groups. The neonatal death rates were also similar (betamethasone vs placebo 0.25 vs 0.24). The only difference seen was an unexpected reduction in the betamethasone group in the incidence of grades 3 and 4 intraventricular hemorrhage (betamethasone vs placebo 1/31 vs 9/36, p = 0.01). Therefore this study was unable to demonstrate any beneficial effect of corticosteroids in reducing respiratory distress syndrome at less than 28 weeks' gestation in spite of a sample size that had an 80% likelihood of detecting a 50% reduction in the incidence of respiratory distress syndrome with p = 0.05, which is the minimum reduction seen in virtually all randomized trials in other gestational age groups.